http://archive.fast-edgar.com/20260914/A82ZA62FZZ2R6ZZZ2RZW2ZYP9MW3ZZ22ZI8G
Filed on: September 14, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number: 001-40253
Zhihu Inc.
(Registrant’s Name)
18 Xueqing Road
Haidian District, Beijing 100083
People’s Republic of China
(Address of Principal... (continue reading...)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: September 2026
Commission file number: 001-41557
CLEARMIND MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
As filed with the Securities and Exchange Commission on September 14, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM F-3
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
Radiopharm Theranostics Limited
(Exact name of registrant as specified in its charter)
Not Applicable
(Translation of registrant’s name into English)
Australia Not... (continue reading...)
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to completion dated September 11, 2026
Pricing supplement
To prospectus dated April 17, 2026,
prospectus supplement dated April 17, 2026 and
product supplement no. 1-I... (continue reading...)
More SEC Filings
View Older Stories-
Form 424B2 JPMORGAN CHASE & CO
-
Form FWP JPMorgan Chase Financial Filed by: JPMorgan Chase Financial Co. LLC
-
Form FWP JPMORGAN CHASE & CO Filed by: JPMORGAN CHASE & CO
-
Form 6-K Li Auto Inc. For: Sep 14
-
Form D/A Sage Partners Alpha 1
-
Form SCHEDULE 13G/A Grab Holdings Ltd Filed by: TOYOTA MOTOR CORP/
-
Form 3 Polar Power, Inc. For: Aug 17 Filed by: Ahern Jim
-
Form SCHEDULE 13G Safe Pro Group Inc. Filed by: FROST PHILLIP MD ET AL
-
Form 8-K WhiteFiber, Inc. For: Sep 14
-
Form 6-K PRUDENTIAL PLC For: Sep 14
-
Form S-1/A Electra Therapeutics,
-
Form 4 Alibaba Group Holding For: Sep 10 Filed by: Wu Yongming
-
Form 1-SA McQueen Labs Series, For: Jun 30
-
Form C/A Oravanti Ventures Inc
-
Form S-3ASR Tyra Biosciences, Inc.
-
Form DEF 14C SHARING ECONOMY INTERNAT For: Sep 14
-
Form 424B2 Jefferies Financial Grou
-
Form 6-K WOODSIDE ENERGY GROUP For: Sep 14
-
Form 15-12G Apogee Therapeutics,
-
Form 8-K Artificial Intelligence For: Sep 14
-
Form EFFECT ACCURAY INC
-
Form 6-K Biophytis SA For: Sep 11
-
Form FWP ROYAL BANK OF CANADA Filed by: ROYAL BANK OF CANADA
-
Form 6-K KE Holdings Inc. For: Sep 14
-
Form 4 NEONC TECHNOLOGIES HOLDI For: Sep 11 Filed by: Heshmatpour Amir F
-
Form EFFECT Eightco Holdings Inc.
-
Form EFFECT Wheeler Real Estate Inve
-
Form 6-K Nanobiotix S.A. For: Sep 14
-
Form EFFECT Strategic Storage Trust
-
Form EFFECT VS MEDIA Holdings Ltd
-
Form EFFECT Indivior Pharmaceuticals
-
Form 8-K ORACLE CORP For: Sep 12
-
Form 6-K NOMURA HOLDINGS INC For: Sep 14
-
Form EFFECT Nasus Pharma Ltd
-
Form EFFECT ENIGMATIG LTD
-
Form EFFECT First Breach, Inc.
-
Form EFFECT Regan Capital Alternativ
-
Form SUPPL THOMSON REUTERS CORP
-
Form 424B2 GOLDMAN SACHS GROUP INC
-
Form 424B5 Thomson Reuters (Tax & Filed by: West Publishing Corp
-
Form EFFECT Can-Fite BioPharma Ltd.
-
Form 1-SA LianSheng Group Inc For: Jun 30
-
Form EFFECT Calisa Acquisition Corp
-
Form S-1/A Eaglesky Acquisition
-
Form 6-K Cellectis S.A. For: Sep 14
-
Form 6-K Caledonia Mining Corp For: Sep 14
-
Form EFFECT Can-Fite BioPharma Ltd.
-
Form 485BXT Spinnaker ETF Series
-
Form FWP BANK OF MONTREAL /CAN/ Filed by: BANK OF MONTREAL /CAN/
-
Form FWP BARCLAYS BANK PLC Filed by: BARCLAYS BANK PLC
